Clinical trials: Visceral Adipose Tissue Accumulation
Obesity, Intra-Abdominal Fat
Effect of a Probiotic on Visceral Fat Accumulation
The study's main objective is to investigate if an extract containing the probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the accumulation of abdominal visceral fat in people with…
- Conditions
- Obesity, Intra-Abdominal Fat, Subcutaneous Fat, Abdominal
- Trial name
- BIFFAT (NCT02921217)
- Testing
- Active Probiotic, Inactivated probiotic, Control
- Where
- Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Menopause, Visceral Adipose Tissue Accumulation
Developing an Intervention to Prevent Visceral Adipose Tissue Accumulation
The aim of this study is to develop an intervention that will produce a sustained improvement in physical activity and chronic stress as a means to slow the menopause-related accumulation of visceral adipose tissue in mid-life…
- Conditions
- Menopause, Visceral Adipose Tissue Accumulation, Abdominal Obesity, Obesity
- Trial name
- NCT01778712
- Testing
- Multi-level intervention
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Diabete Mellitus
Cardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize
calculate cardiovascular risk scores in type 2 DM patients, then estimate its association with new visceral adipose tissue indices
- Trial name
- NCT07204782
- Where
- Egypt
- Volunteers
- 238 people
- Sponsor
- Assiut University
Coronary Artery Calcification
Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification
Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death.
- Trial name
- NCT01158066
- Testing
- CT Cardiac
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Ziv Hospital
Epicardial Fat, Visceral Fat
Epicardial Fat, Visceral Fat and Coronary Atherosclerosis
Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease.
- Conditions
- Epicardial Fat, Visceral Fat, Atherosclerosis
- Trial name
- NCT01344694
- Testing
- patient with liver fat, pts. with excess of visceral fat, control
- Where
- Israel
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Hypertension
Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients
To investigate the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid-metabolism in the hypertensive patients with the accumulation of visceral fat by the newly developed Tele-medicine system
- Trial name
- NCT00288717
- Testing
- Candesartan, Telmisartan
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Saitama Medical University
HIV
Eplerenone in HIV Associated Abdominal Fat Accumulation
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals.
- Trial name
- NCT01405456
- Testing
- Eplerenone and lifestyle
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
HIV Infections, Lipodystrophy
Raltegravir Therapy for Women With HIV and Fat Accumulation
Ritonavir-boosted protease inhibitor (PI) regimens have become a backbone for treatment of people with HIV. However, adverse drug effects, particularly lipodystrophy/lipoatrophy are closely associated with these regimens.
- Trial name
- NCT00656175
- Testing
- raltegravir
- Where
- 5 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- University of California, Los Angeles
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University